Wednesday, January 21, 2009

Are Lawmakers Finally Showing Concern Over Counterfeit Medications and Bioterrorism?

By Alan Clock, Senior Vice President, XStream Systems, Inc.

Drug Store News reported that US Lawmakers and Analysts are finally beginning to question the globalization of the pharmaceutical supply chain, namely the disproportionate amount of manufacturing and raw materials that are produced overseas in countries like China and India.

With the rapid rise of counterfeit medications and food products in these countries within their own population it seems likely that the US domestic pharmaceutical supply will also see a significant rise in reported and unreported incidents of counterfeit medications and the rise in likelihood of bioterrorist threats.

Without the use of a variety of anti-counterfeiting methods and solutions, the US consumer will be at greater risk in 2009 than ever before.

XStream continues to work with agencies, regulators and industry thought leaders to introduce its authentication technology as a solution to safeguarding supply chain inventories. Its technology allows the manufacturer, distributor and dispenser the ability to authenticate the product within its sealed, unit-of-sale container.

The full Drug Store News article is available here:

By Alaric Dearment

New York (Jan. 20)Concern has arisen about the manufacturing of ingredients for drugs in other countries, especially antibiotics like penicillin, according to published reports.

Drug manufacturing has mostly moved to countries such as India and China, but some lawmakers and analysts have said it increases the risks of counterfeits and bioterrorism.

Already, more than 200 Americans have experienced dangerous drug reactions since November 2007 after taking counterfeit versions of the blood-thinning drug heparin manufactured in China containing a toxic chemical that merely mimics heparin. Last November, the Food and Drug Administration confiscated 11 lots of counterfeit heparin from a company based in Cincinnati.

No comments: